At 6.8% CAGR, the Europe Coagulation Market is Projected to be Worth US$ 3,379.71 Million by 2030, Says Business Market Insights

According to Business Market Insights research, the Europe coagulation market was valued at US$ 2,000.64 million in 2022 and is expected to reach US$ 3,379.71 million by 2030, registering a CAGR of 6.8% from 2022 to 2030. Growing organic and inorganic strategies by key market players and increasing prevalence of blood disorders are among the critical factors attributed to the Europe coagulation market expansion.

Changing lifestyle habits and a growing geriatric population are among the major factors increasing the prevalence of blood disorders. Therefore, there is a growing demand for early diagnosis and treatment. Key players are taking several initiatives through various organic and inorganic strategies to enhance the quality of life of patient population.

In June 2021, Trivitron Healthcare introduced NANO H5 and NANO H110, which help in monitoring diabetes, hemoglobin variations, and thalassemia.

In February 2021, Siemens Healthineers and Sysmex Corporation renewed their agreement to supply, distribute, sell, and service hemostasis products across the world. The agreement also included an extension for multiple years. Further, Siemens Healthineers agreed to distribute Sysmex's automated blood coagulation analyzer, such as the CN-3000 and CN-6000.

In July 2022, HORIBA Medical launched the latest Yumizen G800 and G1550 hemostasis analyzers, as well as a range of convenient ready-to-use reagents for common blood coagulation Offerings. With this expansion of its product line, HORIBA Medical now offers a comprehensive selection of hemostasis systems and advanced reagents for laboratories of all sizes and requirements.

Thus, the adoption of various organic and inorganic strategies by the key market players is expected to provide opportunities for the coagulation market growth during the forecast period

On the contrary, high costs associated with coagulation analyzers hampers the growth Europe coagulation market.

Based on disease indication, the Europe coagulation market is segmented into vitamin k deficiency, liver disease, disseminated intravascular coagulation and pulmonary embolism, development of circulating anticoagulants, hemophilia, von willebrand's disease, and others. The liver disease segment held 54.5% share of the Europe coagulation market in 2022, amassing US$ 1,089.56 million. It is projected to garner US$ 1,816.37 million by 2030 to expand at 6.6% CAGR during 2022-2030.

Based on type, the Europe coagulation market is bifurcated into clinical laboratory analysers and point-of-care testing analyzers. The clinical laboratory analysers segment held 68.1% share of the Europe coagulation market in 2022, amassing US$ 1,363.36 million. It is projected to garner US$ 2,209.50 million by 2030 to expand at 6.2% CAGR during 2022-2030. Clinical laboratory analysers is further subsegmented into controls & calibrators, assays & reagents, instruments/systems, coagulation factors, and others.

In terms of offering, the Europe coagulation market is bifurcated into diagnosis and treatment. The diagnosis segment held 65.4% share of the Europe coagulation market in 2022, amassing US$ 1,308.44 million. It is projected to garner US$ 2,183.42 million by 2030 to expand at 6.6% CAGR during 2022-2030. Diagnosis is further subsegmented into prothrombin time testing, fibrinogen testing, activated clotting time testing, activated partial thromboplastin time testing, d-dimmer testing, platelets function testing, and others. Treatment is further subsegmented into anti-fibrinolytic drugs, birth control pills, desmopressin & immunosuppressive medicines, vitamin k supplements, blood thinners, thrombin inhibitors or thrombolytics, replacement therapy, catheter-assisted thrombus removal, and others.

By technology, the Europe coagulation market is segmented into optical technology, mechanical technology, electrochemical technology, and others. The optical technology segment held 60.6% share of Europe coagulation market in 2022, amassing US$ 1,211.83 million. It is projected to garner US$ 2,071.36 million by 2030 to expand at 6.9% CAGR during 2022-2030.

By end user, the Europe coagulation market is segmented into clinical laboratories, hospitals, and others. The hospitals segment held 59.7% share of Europe coagulation market in 2022, amassing US$ 1,194.52 million. It is projected to garner US$ 2,047.29 million by 2030 to expand at 7.0% CAGR during 2022-2030.

Based on country, the Europe coagulation market is categorized into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Germany held 29.7% share of Europe coagulation market in 2022, amassing US$ 593.49 million. It is projected to garner US$ 993.12 million by 2030 to expand at 6.6% CAGR during 2022-2030.

Key players operating in the Europe coagulation market are F. Hoffmann-La Roche Ltd; Genrui Biotech Co., Ltd.; Horiba Ltd; ImproGen Diagnostik Kimya San. & Tic. Ltd.Şti; Siemens Healthineers AG; Sysmex Corp; Transasia Bio-Medicals Ltd; and Nordic Biomarker AB, among others.

In Feb 2021, Siemens Healthineers and Sysmex Extend Hemostasis Agreement. Siemens Healthineers and Sysmex Corporation announced the renewal of the companies' long-standing global supply, distributorship, sales and service agreement for a broad portfolio of hemostasis products including a multi-year extension. As part of the agreement Siemens Healthineers will distribute the new Sysmex CN Systems.

In Aug 2021, Siemens Healthineers Launched Sysmex CN-3000 and CN-6000 Hemostasis Systems. This fully automated CN-3000 and CN-6000 Systems bring mid- and high-volume coagulation testing to laboratories.


Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com